Antoine FORTUNE  

Parcours et intérêts

1997 : DEA (MASTER) Synthèse et Modélisation - Aix-Marseille II
1998 : DESS (MASTER) Informatique - Aix-Marseille II
1999 : Ingénieur d'Etudes Modélisation Moléculaire - U. Montpellier II.
2006 : Doctorat Sciences du médicament : modélisation moléculaire - U. Grenoble 1

Publications

• Article • Exploring the Structure-Activity Relationship of Benzylidene-2,3-Dihydro-1H-Inden-1-One Compared to Benzofuran-3(2H)-One Derivatives as Inhibitors of Tau Amyloid Fibers [Full paper ]

  Emeline Boukherrouba, Camille Larosa, Kim-Anh Nguyen, Jérémy Caburet, Laurent Lunven, Hugues Bonnet, Antoine Fortuné, Ahcène Boumendjel, Benjamin Boucherle, Sabine Chierici, Marine Peuchmaur

  Eur. J. Med. Chem. 2022, 231, 114139

• Article • Targeting different binding sites in the CFTR structures allows to synergistically potentiate channel activity [Full paper ]

  L. Froux, A. Elbahnsi, B. Boucherle, A. Billet, N. Baatallah, B. Hoffmann, J. Alliot, R. Zelli, W. Zeinyeh, R. Haudecoeur, A. Fortuné, S. Mirval, C. Simard, P. Lehn, J.-P. Mornon, I. Callebaut, J.-L. Décout

  Eur. J. Med. Chem. 2020, 190, 112116

• Article • Chimeric Protein-Protein Interface Inhibitors Allow Efficient Inhibition of Type III Secretion Machinery and Pseudomonas aeruginosa Virulence [Full paper ]

  Ngo, T.-D.; Plé, S.; Thomas, A.; Barette, C.; Fortuné, A.; Bouzidi, Y.; Fauvarque, M.-O.; Pereira de Freitas, R.; Francisco Hilário, F.; Attrée, I.; Wong, Y.-S.; Fraudry, E.

  ACS Infect. Dis.

• Article • New 7-methylguanine derivatives targeting the influenza PB2 cap-binding domain. [Full paper ]

  S. Pautus, P. Sehr, J. Lewis, A. Fortuné, A. Wolkerstorfer, O. Szolar, D. Guilligay, T. Lunardi, J.-L. Decout, S. Cusack.

  J. Med. Chem. 2013, 56, 8915-8930.

• Article • New Pseudodimeric Aurones as Palm Pocket Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerase [Full paper ]

  Amel Meguellati, Abdelhakim Ahmed-Belkacem, Alessandra Nurisso, Wei Yi, Rozenn Brillet, Nawel Berqouch, Laura Chavoutier, Antoine Fortuné, Jean-Michel Pawlotsky, Ahcène Boumendjel, Marine Peuchmaur

  Eur. J. Med. Chem. 2016, 115, 217-229

• Oral Comm • Une approche rationnelle pour la thérapie de la mucoviscidose 

  Benjamin Boucherle

• Oral Comm • Discovery of novel tailored F508del-CFTR binder correctors based on 3D structure models of entire CFTR protein for treating Cystic Fibrosis 

  Clément Boinot, Mathilde Jollivet Souchet, Brice Hoffmann, Jean-Paul Mornon, Benjamin Boucherle, Antoine Fortuné, Jean-Luc Decout, Pierre Lehn, Isabelle Callebaut, Frédéric Becq

• Oral Comm • Models of the 3D structure of CFTR: from the understanding of the protein functions to the design of correctors  

  Brice Hoffmann, Jean-Paul Mornon, Benjamin Boucherle, Antoine Fortuné, Romain Haudecoeur, Clément Boinot, Mathilde Jollivet, Jean-Luc Decout, Frédéric Becq, Pierre Lehn, Isabelle Callebaut

• Article • A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo. 

  B. Boucherle, J. Bertrand, B. Maurin, B.-L. Renard, A. Fortuné, B. Tremblier, F. Becq, C. Norez, J.-L. Decout.

  Eur. J. Med. Chem. 2014, 83, 455-465.

• Patent • Compounds for treating cystic fibrosis 

  Isabelle Callebaut, Jean-Paul Mornon, Jean-Luc Decout, Frédéric Becq, Pierre Lehn, Brice Hoffmann, Benjamin Boucherle, Romain Haudecoeur, Antoine Fortuné, Clément Boinot, Julien Alliot

  2014 • 

• Article • Could we expect new praziquantel derivatives? A meta pharmacometrics/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature [Full paper ]

  V.B. Ribeiro da Silva, B. Boucherle, J. El-Methni, B. Hoffmann, A.L. da Silva, A. Fortune, M. do Carmo Alves de Lima, A. Thomas

  SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2019, VOL. 30, NO. 6, 383–401

• Article • Discovery of the Naturally Occurring Aurones as Potent and non Toxic Allosteric Inhibitors of Hepatitis C Virus Polymerase(NS5B) 

  R. Haudecoeur, A. Ahmed-Belkacem, W. Yi, A. Fortune, R. Brillet, C. Belle, E. Nicolle, J.-M. Pawlotsky, A. Boumendjel

  J. Med. Chem. 2011, 54, 5395–5402.

• Article • 2-Arylidenedihydroindole-3-ones: Design, synthesis, and biological activity on bladder carcinoma cell lines. 

  B. Gerby, A. Boumendjel, M. Blanc, P. P. Bringuier, P. Champelovier, A. Fortune, X. Ronot, J. Boutonnat.

  Bioorg. Med. Chem. Lett. 2007, 17, 208-213.

• Article • Towards a better understanding of the basis of molecular mimicry of polysaccharide antigens by peptides : The example of Shigella flexneri 5a 

  Marie-Jeanne Clement, Antoine Fortune, Armelle Phalipon, Veronique Marcel-Peyre, Catherine Simenel, Anne Imberty, Muriel Delepierre, and Laurence A. Mulard

  J. Biol. Chem., 2006, 281, 2317-2332

• Thesis • Techniques de Modélisations Moléculaires Appliquées à l'Etude et à l'Optimisation de Molécules Immunogènes et de Modulateurs de la Chimiorésistance. 

  Antoine Fortuné

  2006 • Université Joseph Fourrier (Grenoble 1)

• Article • mROC: a computer program for combining tumour markers in predicting disease states. 

  Kramar A, Faraggi D, Fortune A, Reiser B.

  Computer Methods and Programs in Biomedicine, 2001, 66:199-207